{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:33:21Z","timestamp":1790973201984,"version":"4.1.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The discovery of the JAK2V617F mutation in most patients with Ph-negative myeloproliferative neoplasms has led to the development of JAK2 kinase inhibitors. However, JAK2 inhibitor therapy has shown limited efficacy and dose-limiting hematopoietic toxicities in clinical trials. In the present study, we describe the effects of vorinostat, a small-molecule inhibitor of histone deacetylase, against cells expressing JAK2V617F and in an animal model of polycythemia vera (PV). We found that vorinostat markedly inhibited proliferation and induced apoptosis in cells expressing JAK2V617F. In addition, vorinostat significantly inhibited JAK2V617F-expressing mouse and human PV hematopoietic progenitors. Biochemical analyses revealed significant inhibition of phosphorylation of JAK2, Stat5, Stat3, Akt, and Erk1\/2 in vorinostat-treated, JAK2V617F-expressing human erythroleukemia (HEL) cells. Expression of JAK2V617F and several other genes, including GATA1, KLF1, FOG1, SCL, C\/EPB\u03b1, PU.1, and NF-E2, was significantly down-regulated, whereas the expression of SOCS1 and SOCS3 was up-regulated by vorinostat treatment. More importantly, we observed that vorinostat treatment normalized the peripheral blood counts and markedly reduced splenomegaly in Jak2V617F knock-in mice compared with placebo treatment. Vorinostat treatment also decreased the mutant allele burden in mice. Our results suggest that vorinostat may have therapeutic potential for the treatment of PV and other JAK2V617F-associated myeloproliferative neoplasms.<\/jats:p>","DOI":"10.1182\/blood-2011-02-336743","type":"journal-article","created":{"date-parts":[[2012,3,10]],"date-time":"2012-03-10T14:06:06Z","timestamp":1331388366000},"page":"3779-3789","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Efficacy of vorinostat in a murine model of polycythemia vera"],"prefix":"10.1182","volume":"119","author":[{"given":"Hajime","family":"Akada","sequence":"first","affiliation":[{"name":"Departments of Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Akada","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Gajra","sequence":"additional","affiliation":[{"name":"Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Bair","sequence":"additional","affiliation":[{"name":"Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Graziano","sequence":"additional","affiliation":[{"name":"Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hutchison","sequence":"additional","affiliation":[{"name":"Pathology, State University of New York Upstate Medical University, Syracuse, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golam","family":"Mohi","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111808512312800_B1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111808512312800_B2","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders.","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"issue":"7037","key":"2019111808512312800_B3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"4","key":"2019111808512312800_B4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9464","key":"2019111808512312800_B5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"2019111808512312800_B6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111808512312800_B7","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111808512312800_B8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.febslet.2011.02.032","article-title":"Differential biological activity of disease-associated JAK2 mutants.","volume":"585","author":"Zou","year":"2011","journal-title":"FEBS Lett"},{"issue":"6","key":"2019111808512312800_B9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis.","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111808512312800_B10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis.","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808512312800_B11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors.","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"issue":"3","key":"2019111808512312800_B12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis.","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"issue":"15","key":"2019111808512312800_B13","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis.","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808512312800_B14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"issue":"17","key":"2019111808512312800_B15","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2005.16.600","article-title":"Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.","volume":"23","author":"Bhalla","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111808512312800_B16","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1182\/blood-2003-07-2431","article-title":"Modification of hematopoietic stem cell fate by 5aza 2\u2032deoxycytidine and trichostatin A.","volume":"103","author":"Milhem","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111808512312800_B17","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1158\/0008-5472.CAN-04-3063","article-title":"Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.","volume":"65","author":"De Felice","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"2019111808512312800_B18","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/0008-5472.CAN-04-3011","article-title":"Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells.","volume":"65","author":"Bug","year":"2005","journal-title":"Cancer Res"},{"issue":"2006","key":"2019111808512312800_B19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.exphem.2005.10.002","article-title":"Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents.","volume":"34","author":"Araki","year":"2006","journal-title":"Exp Hematol"},{"issue":"8","key":"2019111808512312800_B20","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1182\/blood-2006-07-035287","article-title":"Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential.","volume":"109","author":"Araki","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111808512312800_B21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent.","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"issue":"9","key":"2019111808512312800_B22","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/sj.leu.2404860","article-title":"The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.","volume":"21","author":"Golay","year":"2007","journal-title":"Leukemia"},{"issue":"13","key":"2019111808512312800_B23","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/0008-5472.CAN-07-0572","article-title":"Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Res"},{"issue":"24","key":"2019111808512312800_B24","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2019111808512312800_B25","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1073\/pnas.191208598","article-title":"The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.","volume":"98","author":"Ruefli","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"52","key":"2019111808512312800_B26","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.0408345102","article-title":"Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.","volume":"101","author":"Shao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111808512312800_B27","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"issue":"17","key":"2019111808512312800_B28","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111808512312800_B29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111808512312800_B30","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/10428190802527699","article-title":"Enhanced histone deacetylase enzyme activity in primary myelofibrosis.","volume":"49","author":"Wang","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"2019111808512312800_B31","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1182\/blood-2010-02-269696","article-title":"Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD\/SCID marrow repopulating cells.","volume":"116","author":"Wang","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111808512312800_B32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00277-008-0640-3","article-title":"Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.","volume":"88","author":"Lee","year":"2009","journal-title":"Ann Hematol"},{"issue":"4","key":"2019111808512312800_B33","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).","volume":"22","author":"Guerini","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"2019111808512312800_B34","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/blood-2007-07-102848","article-title":"Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.","volume":"111","author":"Grebien","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111808512312800_B35","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":"Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2019111808512312800_B36","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2019111808512312800_B37","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Bone-marrow responses in polycythemia vera.","volume":"290","author":"Prchal","year":"1974","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111808512312800_B38","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.","volume":"100","author":"Gorre","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111808512312800_B39","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","article-title":"Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.","volume":"105","author":"George","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111808512312800_B40","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation.","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"47","key":"2019111808512312800_B41","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/sj.onc.1210761","article-title":"Transcriptional control of erythropoiesis: emerging mechanisms and principles.","volume":"26","author":"Kim","year":"2007","journal-title":"Oncogene"},{"issue":"12","key":"2019111808512312800_B42","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20102260","article-title":"Networking erythropoiesis.","volume":"207","author":"Kerenyi","year":"2010","journal-title":"J Exp Med"},{"issue":"47","key":"2019111808512312800_B43","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1038\/sj.onc.1210764","article-title":"Transcriptional control of granulocyte and monocyte development.","volume":"26","author":"Friedman","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"2019111808512312800_B44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1091581809352111","article-title":"Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.","volume":"29","author":"Kerr","year":"2010","journal-title":"Int J Toxicol"},{"issue":"10","key":"2019111808512312800_B45","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1172\/JCI42442","article-title":"HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.","volume":"120","author":"Marubayashi","year":"2010","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111808512312800_B46","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.","volume":"111","author":"Wernig","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111808512312800_B47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mc.20777","article-title":"Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2\/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.","volume":"51","author":"Xiong","year":"2012","journal-title":"Mol Carcinog"},{"issue":"1","key":"2019111808512312800_B48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2141.2005.05416.x","article-title":"Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2.","volume":"129","author":"Goerttler","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111808512312800_B49","doi-asserted-by":"crossref","first-page":"e22148","DOI":"10.1371\/journal.pone.0022148","article-title":"JAK2 V617F-dependent upregulation of PU. 1 expression in the peripheral blood of myeloproliferative neoplasm patients.","volume":"6","author":"Irino","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"2019111808512312800_B50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20110540","article-title":"A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.","volume":"209","author":"Kaufmann","year":"2012","journal-title":"J Exp Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/16\/3779\/1476454\/zh801612003779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/16\/3779\/1476454\/zh801612003779.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T09:58:03Z","timestamp":1574071083000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/16\/3779\/29956\/Efficacy-of-vorinostat-in-a-murine-model-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":50,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,4,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-336743","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,19]]}}}